ClinicalTrials.gg

Program

PF-08046044

A development code. Also written as “PF-08046044/SGN-35C”.

In Pfizer's pipeline, CD30-directed antibody TOPO1 drug conjugate. Its studies are mostly in Hodgkin Disease, led by Pfizer.

Furthest: phase 1, since Feb 2, 20241 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer10 open or runningphase 1since Feb 2, 2024Feb 2, 2024none ahead
  • Named in Pfizer’s own pipeline as PF-08046044, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 2, 2024First study: phase 1 study in Hodgkin DiseaseFirst studyNCT06254495 · 58 enrolled · United States, Denmark, France and more

TargetBeta

“CD30-directed antibody TOPO1 drug conjugate”the company's pipeline, read by Claude · source

Other programs on TNFRSF8

ProgramCompanyFurthest phaseStudies
Brentuximab VedotinrulePfizerphase 437

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06254495Hodgkin Disease · United States, Denmark, France and more1TerminatedApr 13, 202658

How it is read

Names in the registry

  • “PF-08046044/SGN-35C”, 1 entry

Codes read as this program: PF08046044.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.